- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8720
| Related Targets | K-Ras CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras |
|---|---|
| Other Adenosine Receptor Products | Reversine CGS 21680 HCl ZM241385 SCH58261 A2AR antagonist 1 Ciforadenant (CPI-444) Namodenoson (CF-102) Derenofylline (SLV320) Proxyphylline Capadenoson |
|
In vitro |
DMSO
: 63 mg/mL
(199.53 mM)
Ethanol : 4 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 315.73 | Formula | C15H11ClFN5 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1321514-06-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | HTL1071 | Smiles | CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F | ||
| Targets/IC50/Ki |
A2AR
(Cell-free) 1.7 nM(Ki)
|
|---|---|
| In vitro |
In CHO cells stably expressing human A2AR, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM in the presense of 0.1, 1 and 10 μM adenosine, respectively. |
| In vivo |
Blockade of A2AR signaling with AZD4635 could reduce tumor burden and enhance antitumor immunity. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04495179 | Completed | Progressive Metastatic Castrate-Resistant Prostate Cancer |
AstraZeneca|Parexel |
August 4 2020 | Phase 2 |
| NCT04089553 | Completed | Prostate Cancer|Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
AstraZeneca |
August 29 2019 | Phase 2 |
| NCT03381274 | Active not recruiting | Carcinoma Non-Small-Cell Lung |
MedImmune LLC |
May 8 2018 | Phase 1|Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.